Clinical trials: Primary Neoplasm
Meningococcal Disease
Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)
The purpose of this extension study is to evaluate the immunogenicity and safety of a booster dose of a MenABCWY vaccine, administered 24 months after completion of the primary vaccination series, in subjects who previously…
- Trial name
- NCT01992536
- Testing
- MenABCWY+OMV, MenABCWY+¼OMV
- Where
- 13 sites in United States, Poland
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Depression, Non-psychotic Diagnosis as Co-morbidity
The Canadian Armed Forces PEER Study
This is a prospective, single-blinded, randomized, multicenter study to evaluate the utility, safety, and efficacy of using PEER Interactive - an EEG-based technology - to inform the prescription of medications to participants…
- Trial name
- PEERCanada (NCT03625271)
- Testing
- The PEER Report
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- MYnd Analytics
Sleep Initiation and Maintenance Disorders, Insomnia
Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia
This study is designed to determine whether morning doses of GW679769, taken daily for 1 to 9 days, will promote sleep during the following night without significant post-dose thinking impairment and drowsiness in subjects with…
- Trial name
- NCT00354809
- Testing
- GW679769
- Where
- 24 sites in United States, France and 1 more
- Volunteers
- 68 people
- Sponsor
- GlaxoSmithKline
Male Hypogonadism, Primary Hypogonadism
Pharmacokinetic Study to Determine Time to Steady-state
The purpose of the study is to confirm how long (i.e., how many days) it takes to reach steady-state when testosterone undecanoate is administered twice daily.
- Conditions
- Male Hypogonadism, Primary Hypogonadism, Secondary Hypogonadism
- Trial name
- NCT00911586
- Testing
- Testosterone undecanoate
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Clarus Therapeutics, Inc.
Lupus Nephritis, Immunoglobulin A Nephropathy
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis …
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- RUBY-3 (NCT05732402)
- Testing
- Povetacicept
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 72 people
- Sponsor
- Alpine Immune Sciences, Inc.
Relapsed Epithelial Ovarian Cancer, Relapsed Primary Peritoneal Cancer
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
This is a dose escalation study in female subjects with relapsed ovarian cancer (including epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer).
- Conditions
- Relapsed Epithelial Ovarian Cancer, Relapsed Primary Peritoneal Cancer, Relapsed Fallopian Tube Cancer
- Trial name
- NCT01940172
- Testing
- Birinapant, Conatumumab
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- TetraLogic Pharmaceuticals
Acute Rhinosinusitis
Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Phase 3 Study)(Study P02692)
This study was conducted to compare the effectiveness and safety of mometasone nasal spray once daily or twice daily with amoxicillin or with placebo in treating the signs and symptoms of acute rhinosinusitis.
- Trial name
- NCT00751075
- Testing
- mometasone furoate nasal spray (MFNS), MFNS, Amoxicillin
- Volunteers
- 981 people
- Sponsor
- Organon and Co
Enuresis
A Study to Determine if Ibuprofen in Combination With Pseudoephedrine HCl is More Effective Than Each Drug Alone in the Treatment of Nighttime Bedwetting
The purpose of the study is to determine if ibuprofen in combination with pseudoephedrine HCl in the treatment of nightime bedwetting in children is more effective than each drug alone and if the individual drugs are more…
- Trial name
- NCT00240812
- Testing
- ibuprofen; pseudoephedrine HCl
- Volunteers
- 318 people
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Myelofibrosis (MF)
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.
- Trial name
- REFINE (NCT03222609)
- Testing
- Ruxolitinib, Navitoclax
- Where
- 91 sites in United States, Australia and 12 more
- Volunteers
- 191 people
- Sponsor
- AbbVie
Primary Membranous Nephropathy
A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
This study is a multicenter, randomized, open label, cyclosporine controlled Phase II trial aimed at evaluating the efficacy, safety, pharmacokinetics, and immunogenicity of Zuberitamab in patients with primary membranous…
- Trial name
- NCT06642909
- Testing
- Zuberitamab 600mg, Zuberitamab 1000mg, cyclosporine
- Where
- China
- Volunteers
- 135 people
- Sponsor
- BioRay Pharmaceutical Co., Ltd.
Primary Sjogren's Syndrome
A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome
The purpose of this study is to evaluate the efficacy and safety of subcutaneous Telitacicept versus placebo in subjects with active primary Sjogren's Syndrome.
- Trial name
- NCT05673993
- Testing
- Telitacicept 80 mg, Telitacicept 160 mg
- Where
- 78 sites in China
- Volunteers
- 381 people
- Sponsor
- RemeGen Co., Ltd.
Primary IgA Nephropathy
A Study of SHR-2173 in Participants With Primary IgA Nephropathy
This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in patients with Primary IgA Nephropathy(IgAN).
- Trial name
- NCT07354932
- Testing
- SHR-2173 injection
- Where
- 2 sites in China
- Volunteers
- 84 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Osteoarthritis, Total Knee Arthroplasty
Use of Cold and Compression Therapy With Total Knee Replacement Patients
The purpose of the study is to evaluate the effectiveness of a device that delivers cold and intermittent compression as compared to ice and compressive wraps on patients who have undergone knee replacement.
- Trial name
- NCT00712816
- Testing
- Game Ready Injury Treatment System (CoolSystems Inc.), Ice with compressive bandages
- Where
- 11 sites in United States, Australia
- Volunteers
- 224 people
- Sponsor
- CoolSystems, Inc.
Primary Sjögren's Syndrome
Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome
This Study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary therapeutic efficacy of oral administrations of CDZ173 in patients with primary Sjögren's syndrome.
- Trial name
- NCT02775916
- Testing
- CDZ173
- Where
- 2 sites in Germany, Hungary
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Extension to Study of Effects of Pomegranate Extract on Rising PSA Levels After Primary Therapy for Prostate Cancer
High concentrations of anti-oxidants in pomegranate seeds present a potential strategy to delay clinical prostate cancer progression and prolong the interval from primary treatment failure to hormonal ablation.
- Trial name
- NCT00732043
- Testing
- pomegranate extract, pomegranate juice
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Roll International Corporation
Primary Hyperaldosteronism
Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.
Parent study: This is a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of baxdrostat versus placebo, on the reduction of Seated Blood…
- Trial name
- BaxPA (NCT07007793)
- Testing
- Baxdrostat
- Where
- 76 sites in United States, Australia and 10 more
- Volunteers
- 212 people
- Sponsor
- AstraZeneca
Diphtheria, Tetanus
Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants
This study will assess both the antibody persistence of the investigational vaccine and the immune response and safety of a booster dose of PENTAXIM™ vaccine in 18 months-old toddlers who participated in an earlier study in order…
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- NCT00303316
- Testing
- DTaP-IPV//PRP~T combined vaccine
- Where
- Argentina
- Volunteers
- 458 people, healthy volunteers welcome
- Sponsor
- Sanofi
Morbidity
A Pilot Study for Adaptation of Neospot Device for Health Care at Primary Health Facilities in Kenya
Neospot device is a 5-in-1 wearable vital signs monitor designed to measure temperature, blood pressure, pulse rate (PR), respiratory rate (RR) and blood oxygen saturation (SPO2).
- Trial name
- NCT06132633
- Testing
- Neospot vitals measurement
- Where
- Kenya
- Volunteers
- 159 people
- Sponsor
- Neopenda, PBC
Migraine
Consistency of Response With Rimegepant in Acute Treatment of Migraine
This is a non-interventional, prospective study that will enroll participants with migraine in the United Kingdom currently in use of rimegepant to acutely treat migraine attacks.
- Trial name
- CORRELATE-UK (NCT06898047)
- Testing
- Rimegepant for acute migraine treatment
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Pfizer
Infections, Meningococcal
Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine
The purpose of this study is to compare the immediate and long term (up to 5 years) immunogenicity and safety of GSK Biologicals' MenACWY-TT vaccine when given as a single dose or as 2 doses to toddlers aged 12 to 14 months.
- Trial name
- NCT01939158
- Testing
- Meningococcal vaccine GSK134612, Prevenar 13™
- Where
- 51 sites in Australia, Canada and 4 more
- Volunteers
- 803 people, healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.